Sunday, July 26, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
110

Quick answer

110 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12186282

    Treatment of 22Q11.2 deletion syndrome with cannabidiol

    Harmony Biosciences Management, Inc. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12187739

    Diaryl macrocycle polymorph

    TURNING POINT THERAPEUTICS, INC. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12186306

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12194150

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12194016

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12201639

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12201604

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12201596

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12202832

    Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    ALPHA COGNITION INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12208092

    Compositions and methods for administering paltusotine to patients with hepatic impairment

    CRINETICS PHARMACEUTICALS, INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12214021

    Study on lactoferrin regulation of bone formation by means of vitamin D receptor

    China Agricultural University · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12213951

    Treatment of autism with cannabidiol

    Harmony Biosciences Management, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12213964

    Isoxazoline parasiticide formulations

    Tarsus Pharmaceuticals, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12213989

    Use of maribavir in treatment regimens

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12214083

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12220409

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12221452

    Synthesis of cantharidin

    Verrica Pharmaceuticals Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12226373

    Treatment of fragile X syndrome with cannabidiol

    Harmony Biosciences Management, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12226610

    Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions

    Pacira Pharmaceuticals, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12233042

    Treatment of cutaneous disorders

    Verrica Pharmaceuticals Inc. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12233105

    Methods for storing and warming purified corticotropin compositions

    ANI Pharmaceuticals, Inc. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12233166

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12246092

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12246023

    Use of reboxetine to treat narcolepsy

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12251468

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12251472

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12257224

    Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

    Milestone Pharmaceuticals Inc. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12257242

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12263149

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12263148

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12263145

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12263139

    Use of cannabidiol in the treatment of tuberous sclerosis complex

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Amryt Pharmaceuticals Designated Activity Company · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12268730

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12274696

    Methods of administering nalbuphine

    Trevi Therapeutics, Inc. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 2025120959

    NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE

    BIOPROJET PHARMA [FR] · Granted Thu Apr 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12281113

    Crystalline forms of a KRas G12C inhibitor

    Mirati Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12280149

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12280093

    Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12280037

    Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

    EVOFEM BIOSCIENCES, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12285417

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12285419

    Bupivacaine multivesicular liposome formulations and uses thereof

    Pacira Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12290566

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12290520

    Methods of use of emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

110 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.